-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga·06/18/2026 10:06:18
Listen to the news
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.